Experiment 394318

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismGinkgo biloba (GINKGOACEAE)
CitationHOFFMANN,F: BECK,C: SCHUTZ,A: OFFERMANN,P:. (1994). GINKGO EXTRACT EGB 761 (TENOBIN)/HAES VERSUS NAFTIDROFURYL (DUSODRIL)/HAES. A RANDOMIZED STUDY OF THERAPY OF SUDDEN DEAFNESS.. 73(3)
Amount utilized
Compound isolated
Disease80 PATIENTS WITH IDIOPATHIC SUDDEN HEARING LOSS EXISTING NO LONGER THANT 10 DAYS WERE INCLUDED IN A RANDOMISED REFERANCE-CONTROLLED STUDY. THE THERAPEUTIC VALUE OF GINKGO EGB 761 (TABONIN) + HAES WAS COMPARED TO THAT OF NAFTIDROFURYL (DUSODRIL)+HAES. THE MAIN MECHANISMS OF ACTION OF EGB 761 ARE A VASOREGULATING ACTIVITY (INCREASED BLOOD FLOW), THE PLATELET ACTIVATING FACTOR ANTAGONISM AND A PREVENTION OF MEMBRANE DAMAGE CAUSED BY FREE RADICALS, NAFTIDROFURYL HAS ANTISEROTONERGIC AND THEREFORE VASODILATORY PROPERTIES. THE STATISTICAL ANALYSIS OF THE AUDIOMETRIC DATE WAS PERFORMED IN MEASURING THE RELATIVE HEARING GAIN AS DESCRIBED BY EIBACH 1979. AFTER ONE WEEK OF OBSERVATION, 40% OF THE PATIENTS IN EACH GROUP SHOWED A COMPLETE REMISSION OF HEARING LOSE. THIS WAS ALSO OBSERVED BY OTHER AUTHORS WHO HAD COMPARED OTHER DRUGS. THEREFORE, IN THESE CASES, IT IS MOST LIKELY THAT SPOHNTANEOUS RECOVERY IS THE MOST IMPORTANT FACTOR. AFTER TWO AND THREE WEEKS OF OBSERVATION, MEASURING THE RELATIVE HEARING GAIN, THERE WAS A SIGNIFICANT BORDERLINE BENEFIT OF EGB 761 (P = 0.06) WITHOUT ANY SIDE EFFECTS.
Number1
Qualitative resultACTIVE
AnimalHUMAN ADULT
Dose expressionDOSE
ExtractETOH(100%)EXT
GenderGIVEN TO BOTH SEXES